Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7182282
Reference Type
Journal Article
Title
The action of vitamin B1 (thiamine) on the cardiovascular system of the cat
Author(s)
Freye, E; Agoutin, H; ,
Year
1978
Volume
28
Issue
6
Page Numbers
315-319
Language
English
PMID
747722
Abstract
Vitamin B1 administered in a high dose (160 mg/kg) parenterally is known to cause neuromuscular and ganglionic blockade. The effects on the cardiovascular system however have not been sufficiently investigated. In artificially ventilated cats under light ethrane-anesthesia, following parameters were measured continuously before and after B1 administration : Left ventricular pressure, left ventricular end-diastolic pressure, LV dP/dt max, electrocardiogram, heart rate, central venous pressure, and peripheral blood pressure (systolic, diastolic, mean). The data indicate a three-phase reaction after B1 injection : Phase 1--shortly after injection there is a drop of all parameters lasting for 30 sec. The LVEDP showed no change while CVP increased. The drop could not be eliminated by the pretreatment with antihistaminiergic or anticholinergic drug. Sequential stimulation with norepinephrine was able to re-establish base-line values. In Phase 2 (two minutes after injection) all parameters return to their control values ; except CVP which stays elevated. Phase 3 (around the 7th minute after injection) shows a gradual decrease of all parameters; CVP returns to control values. It is suggested that phase 1 represents an immediate alpha-blockade, phase 2 reveals a compensatory reflex mechanism, and phase 3 shows full ganglionic blockade.
Tags
•
PFAS Universe
Data Source
Pubmed
Enflurane
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity